# Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

> **NCT04365400** · PHASE2 · TERMINATED · sponsor: **Afimmune** · enrollment: 233 (actual)

## Conditions studied

- Hypertriglyceridemia
- Type 2 Diabetes

## Interventions

- **DRUG:** DS102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04365400
- **Lead sponsor:** Afimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-13
- **Primary completion:** 2022-05-03
- **Final completion:** 2022-05-03
- **Target enrollment:** 233 (ACTUAL)
- **Why stopped:** Trial prematurely terminated on 03 May 2022 due to the results from an interim analysis indicating a lack of efficacy in the study population.
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365400, "Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04365400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*